Assessing the benefit of new pharmaceuticals: Are we talking the same language, can we explain disagreement, and would it be better to do it together?
Editor-in-Chief, Health Policy.
Reinhard
R
Busse
D001315:Australia; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D005060:Europe; D014943:Global Health; D006801:Humans; D013673:Technology Assessment, Biomedical